In situ phase transition of microemulsions for parenteral injection yielding lyotropic liquid crystalline carriers of the antitumor drug bufalin by Li, Yawen et al.
HAL Id: hal-02381456
https://hal.archives-ouvertes.fr/hal-02381456
Submitted on 26 Nov 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
In situ phase transition of microemulsions for parenteral
injection yielding lyotropic liquid crystalline carriers of
the antitumor drug bufalin
Yawen Li, Angelina Angelova, Jianwen Liu, Vasil Garamus, Na Li, Markus
Drechsler, Yabin Gong, Aihua Zou
To cite this version:
Yawen Li, Angelina Angelova, Jianwen Liu, Vasil Garamus, Na Li, et al.. In situ phase transi-
tion of microemulsions for parenteral injection yielding lyotropic liquid crystalline carriers of the
antitumor drug bufalin. Colloids and Surfaces B: Biointerfaces, Elsevier, 2019, 173, pp.217-225.
￿10.1016/j.colsurfb.2018.09.023￿. ￿hal-02381456￿
  1
 
In situ phase transition of microemulsions for 
parenteral injection yielding lyotropic liquid 
crystalline carriers of the antitumor drug bufalin 
 
Yawen Lia, Angelina Angelovab, Jianwen Liua, Vasil M. Garamusc,  
Na Lid, Markus Drechsler e, Yabin Gongf, Aihua Zou a* 
 
a Shanghai Key Laboratory of Functional Materials Chemistry, State Key Laboratory 
of Bioreactor Engineering and Institute of Applied Chemistry, School of Chemistry 
and Molecular Engineering, East China University of Science and Technology, 
Shanghai 200237, P. R. China 
bInstitut Galien Paris-Sud, CNRS UMR 8612, Univ. Paris-Sud, Université 
Paris-Saclay, LabEx LERMIT, F-92296 Châtenay-Malabry cedex, France,  
cHelmholtz-Zentrum Geesthacht, Centre for Materials and Coastal Research, 
D-21502 Geesthacht, Germany  
d National Center for Protein Science Shanghai and Shanghai Institute of 
Biochemistry and Cell Biology, Shanghai 200237, P. R. China 
e Keylab "Electron and Optical Microscopy", Bavarian Polymerinstitute (BPI),  
University of Bayreuth, D-95440 Bayreuth, Germany 
fYueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 
200437, P.R. China 
 
 
 
 
 
*To whom correspondence should be addressed.  
 Tel/Fax: +86-21-64252231 
 E-mail: aihuazou@ecust.edu.cn 
†East China University of Science and Technology. 
  2
Abstract 
In this work, we use the small angle X-ray scattering (SAXS) method for controlled 
preparation of in situ forming sustained-release carriers of the antitumor drug bufalin 
(BUF), which has very poor solubility and a considerable cardiotoxicity in a 
non-encapsulated state. To that aim, we exploit the pseudo-ternary phase diagram of 
an oil(O)/surfactant(S)/water(W) system containing medium chain capric/caprylic 
triglycerides (MCT) and a co-surfactant blend of Macrogol (15)-hydroxystearate 
(Solutol HS 15) and sorbitan monooleate (Span 80). Two compositions with different 
oil contents (B-LC-ME and C-LC-ME) are selected from the microemulsion region of 
the diagram in order to study the effect of the aqueous environment on their structural 
behaviour. A phase transition from a microemulsion to a lamellar liquid crystalline 
phase and multilamellar vesicles is established by SAXS upon progressive dilution. 
The drug bufalin (BUF) is encapsulated in the microemulsions, which have low 
viscosity, whereas the release of the drug occurred from the in situ generated lamellar 
liquid crystalline structures. The formulations are characterized by SAXS, dynamic 
light scattering (DLS), cryogenic transmission electron microscopy (Cryo-TEM), 
rheology, drug loading and entrapment efficiency, and in vitro release profiles. A 
correlation is suggested between the structures of the in situ phase-transition formed 
LC-ME formulations and the differences in their viscosities and drug release profiles. 
The performed cytotoxicity, cell apoptosis and pharmacokinetic experiments show an 
enhanced bioavailability of BUF after encapsulation. These results suggest potential 
clinical applications for the obtained safe in situ phase-transition sustained-release 
formulations of BUF.  
 
 
 
Keywords: bufalin encapsulation,  in situ phase transition, liquid crystalline carrier, 
SAXS, drug release, bioavailability  
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Introduction 
Lipid- and oil-based drug delivery systems are widely used for increasing the 
solubility and bioavailability of hydrophobic drugs [1-5]. Various types of 
nanostructured lipid carriers, liquid crystalline lipid nanoparticles (cubosomes, 
spongosomes, hexosomes, liposomes), microemulsions, nanoemulsions, nanogels, 
solid lipid nanoparticles, and hybrid lipid-polymer nanoparticles have been 
investigated with the aim of encapsulation and protection of poor soluble or instable 
therapeutic molecules [6-15]. The challenges in the development of such formulations 
comprise (i) reduced therapeutic effects owing to rapid drug release from the carriers, 
(ii) drug precipitation at the injection site in the cases when the administered quantity 
exceeds the solubility limit of the hydrophobic drug, and (iii) side effects associated 
with toxicity or immunoreactions [12-15]. Parenteral administration is performed by 
injections, which can be intramuscular, subcutaneous, intralesional, intravitreal, and 
intra-articular among other possible injection sites [16]. So the parenteral routes of 
drug administration are suitable for  treatment of patients using a limited number of 
injections [16]. Therefore, they require new strategies for facile fabrication of 
sustained release delivery systems.  
In situ phase transitions have emerged as a promising strategy for 
sustained-release drug delivery applications based on intramuscular, subcutaneous, 
intra-articular, and intratumoral injections [17-23]. For instance, the phase transition 
from microemulsion (ME) to liquid crystalline (LC) structures appears as an 
alternative to the injectable in situ forming polymeric gels [20,24,25] that may 
provide sustained release profiles of encapsulated drugs. In this approach, the drug 
encapsulation is made in the microemulsion domain of the pseudo-ternary phase 
diagram of appropriate oil/surfactant/water systems, where the formulations have low 
viscosity. Microemulsions (ME) have been extensively studied as drug delivery 
vehicles for various administration routes [9,10, 12-15]. They have a capacity of 
solublizing either lipophilic or hydrophilic drug compounds. The progressive dilution 
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of the microemulsion by water (upon its contact with the aqueous environment in the 
body) may result in the formation of a liquid crystalline (LC) carrier of increased 
viscosity. The latter may favor the diminishment of the drug diffusion rate and 
provide prolonged drug release [17].  
The possibility to exploit in situ phase transitions of drug carrier systems for 
tuning of their physico-chemical properties and drug release kinetics is expected to 
improve the therapeutic outcome of several poor soluble drugs, and in particular, to 
overcome the failure of some of the previously studied delivery systems of bufalin 
(BUF).  
Bufalin (Fig. 1a) is an antitumor compound isolated from the traditional Chinese 
medicine “Chan’su” (toad venom). It is a bufanolide steroid compound. The broad 
spectrum of anticancer activities of BUF has received considerable attention [26-32]. 
The mechanisms of bufalin-induced cell death comprise its (i) influence on the 
expression of apoptosis-related genes, (ii) inhibition of tumor cell proliferation, (iii) 
generation of reactive oxygen species, (iv) endoplasmic reticulum stress, (v) JNK 
(c-Jun N-terminal kinase) activation, (vi) protein kinase modulating effect, (vii) 
caspase- and mitochondria-dependent signaling pathways, and (viii) cell cycle arrest 
via the c-Myc/NF-kappa B pathway [26-37]. Despite that BUF is considered as a 
promising antitumor agent, its poor water solubility, high cardiac toxicity, short 
circulation half-life and narrow therapeutic window have limited the clinical 
application of the drug [26].  
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Fig. 1 (a) Chemical structure of the drug bufalin (BUF). (b) A pseudo-ternary phase 
diagram MCT/HS 15−Span 80/water at 37 oC [17] with an indication of the 
investigated oil(O)/surfactant(S)/water(W) compositions along the dilution lines, 
which are chosen between the regions of microemulsions (ME), liquid crystals (LC), 
and coarse emulsions (CE). The phase transitions of the O/S/W system from ME to 
LC, occurring upon progressive addition of water, are examined by SAXS along the 
lines B−B5 and C−C5.  
 
 
Various types of drug delivery systems have been investigated with the purpose to 
improve the absorption and bioavailability of bufalin in anticancer therapies [33-38]. 
Liposomes coated with citrus pectin have been employed for encapsulation of BUF 
[33]. This carrier system has been more stable in comparison to traditional liposomes, 
but the drug entrapment efficiency was about 49%. Polymer nanoparticle made of 
mPEG-PLGA-PLL-cRGD (methoxy polyethylene glycol (mPEG), 
polylactic-co-glycolic acid (PLGA), poly-L-lysine (PLL), and cyclic 
arginine-glycine-aspartic acid (cRGD)) have been investigated as a potential delivery 
system of BUF in antitumor therapy [34]. Bufalin-loaded mPEG-PLGA-PLL-cRGD 
nanoparticles have been characterized by drug entrapment efficiency (EE) of 
(81.7±0.9)% and drug loading (DL) of (3.92±0.2)%. The use of biotinylated chitosan 
has allowed the preparation of BUF-encapsulating nanoparticles with entrapment 
efficiency of 77.5±2.5% [35].Considering the complexity of the reported preparation 
protocols, their high costs, and the instability of the nanoparticulate formulations, the 
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need of a more simple method for BUF vectorization becomes evident together with 
the requirement for higher stability and drug entrapment efficiency. 
 Here we exploit the structural features of the in-situ phase transition from a 
microemulsion to a lyotropic liquid crystal (LC) toward the aim of controlled 
preparation of bufalin drug-loaded carriers. We use the pseudo-ternary phase diagram 
of an oil(O)/surfactant(S)/water(W) system containing medium chain capric/caprylic 
triglycerides (MCT) and a co-surfactant blend of Macrogol (15)-hydroxystearate 
(Solutol HS 15) and sorbitan monooleate (Span 80) [39] (Fig. 1b). Solutol HS 15 is a 
safety surfactant, which can be sterilized and used in painless injections at 
concentrations as high as 50% (w/w) [40]. All materials employed for the sample 
preparation are biocompatible, injectable, sterilizable, and available in a nonpyrogenic 
grade. Moreover, they are non-hemolytic and non-irritating to the nervous system and 
have been approved by the US Food and Drug Administration (FDA) for 
intramuscular injections [39]. The mixture of Solutol HS 15 (an O/W emulsifying 
agent of hydrophilic nature, HLB=15) and Span 80 (a W/O emulsifying agent of 
lipophilic nature, HLB=4.3) yields an average HLB=12.3 (hydrophilic-lipophilic 
balance) value, which facilitates the in situ phase transition from ME to LC upon 
contact with aqueous phase. 
The aim of this study is to investigate by SAXS the structural changes occurring 
along two dilution lines of the MCT/HS 15-Span 80/water pseudo-ternary phase 
diagram and demonstrate the sustained-release properties of the in situ prepared 
carriers of the antitumor drug BUF. The rationale of using two surfactant molecules in 
this work is based on the fact that they can assemble in the mixture as a double chain 
amphiphile, which spontaneously forms a lamellar phase structures upon hydration. 
The human lung cancer cell line A549 was employed as a cancer cell model for 
evaluation of the biological effects of the encapsulated bufalin.  
 
Material and methods 
2.1 Materials  
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Bufalin ((3β, 5β)-3,14-dihydroxybufa-20,22-dienolide, BUF) was used as 
received from Chengdu Herbpurify Co. Ltd (China). The purity was greater than 98% 
according to the specification from the supplier. Macrogol (15)-hydroxystearate 
(Solutol HS 15) was provided by BASF (Germany). Capric/caprylic triglycerides 
(MCT), sorbitan monooleate (Span 80) and absolute ethyl alcohol were purchased 
from Aladdin Chemical Reagent Co. Ltd. (China). The water used in the experiment 
was double distilled.  
2.2 Sample Preparation   
Two compositions of different contents of oil (MCT) were selected from the 
pseudo-ternary phase diagram reported by Wu et al. [39]. They are shown in Fig.1b as 
points B and C and are referred to as B-LC-ME and C-LC-ME hereafter. Table S1 
presents the materials mass ratios in the investigated starting mixtures B-LC-ME and 
C-LC-ME. The drug BUF was dissolved in absolute ethanol for the preparation of 
BUF-loaded carriers, which were obtained by the same method. Starting from points 
B and C, the water content was increased along the indicated dilution lines (Fig. 1b), 
which served for the preparation of samples B1, B2, B3, B4, B5, C1, C2, C3, C4, and 
C5 (Table S1).  
2.3 Structure characterization  
The small-angle X-ray scattering (SAXS) was performed at the beamline 
BL19U2 of the National Center for Protein Science Shanghai (NCPSS) at Shanghai 
Synchrotron Radiation Facility (SSRF). Rheological measurements were performed 
on a AR 2000 EX rheometer (TA Instruments) at 37 oC. The dynamic light scattering 
(DLS) measurements were performed with a Delsat Nano C Particle Analyzer 
(Beckman Coulter, USA) to get the mean hydrodynamic diameters and their size 
distributions. Cryo-transmission electron microscopy studies were done in laboratory 
for Soft Matter Electron Microscopy, University of Bayreuth.  The experimental 
details were in Electronic Supplementary Information (ESI). 
2.4 Encapsulation efficiency and drug loading 
The encapsulation efficiency (EE) and drug loading (DL) of the BUF 
drug-loading carriers were determined by the ultrafiltration method [7]. The 
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quantitative HPLC analysis method was used to measure the free drug concentration. 
The wavelength was set at 298 nm for the HPLC analysis. The EE and DL were 
estimated using Equations (1) and (2) below: 
     (1) 
      (2), 
where CT, CF, and CL are the total amount of BUF present in the dispersion system, 
the amount of non-entrapped BUF, and the total amount of lipids and  encapsulated 
BUF, respectively.  
2.5 In vitro drug release experiments  
The in vitro release of BUF from LC-ME- BUF was determined by the dialysis 
method. The freshly prepared LC-ME-BUF samples were placed into dialysis tubes 
with 14 kDa MW cutoff. The latter were incubated in the release medium (PBS, 
phosphate buffer saline, pH 7.4; 150 mL) at 37 oC. Samples (4 mL) were taken out 
from the release medium at predetermined time points and the system was refilled 
with the same volume of fresh medium. Subsequently, the BUF content was measured 
by the quantitative HPLC analysis method. 
2.6 Cytotoxicity assay   
The viability of A549 cells, treated with free drug BUF, blank (B-LC-ME and 
C-LC-ME) and BUF-loaded carriers (B-LC-ME-BUF and C-LC-ME-BUF), was 
measured in vitro using a Cell Counting Kit-8 (CCK-8) assay. For this purpose, the 
A549 cells were seeded at a density of 5×103 cells per well in 96-well plates 
containing 100 μL medium per well. After incubation for 24 h, the culture medium 
was removed and the cells were exposed for 48 h to various concentrations of free 
drug BUF or multicomponent formulations (B-LC-ME-BUF, C-LC-ME-BUF, 
B-LC-ME and C-LC-ME) dispersed in the medium. Then, 10 μL of CCK-8 reagent 
was added per well. After incubating the cells for another 1 h, the absorbance was 
recorded at a wavelength of 450 nm using a Spectra Max M5 instrument. The 
GraphPad Prism software (Windows version) was used to calculate the IC50 values 
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(i.e. the 50% inhibiting concentration). 
2.7 Cell apoptosis assay 
The effects of free BUF, B-LC-ME-BUF, C-LC-ME-BUF, B-LC-ME and 
C-LC-ME on the A549 cell apoptosis were assessed using flow cytometry. Briefly, the 
cells were harvested and suspended at a concentration of 2×105 cells/well in six-well 
plates overnight. Then, they were subjected to different types of treatments (free BUF, 
B-LC-ME-BUF, C-LC-ME-BUF, B-LC-ME and C-LC-ME) for 48 h. The cells were 
then collected by centrifugation and washed twice with cold PBS at 1000 rpm for 5 
min. Finally, the cells were gently re-suspended in 500 µL of binding buffer and 
incubated with 5 µL of Annexin V-FITC and 5 µL of PI in dark for 10 min. After 
incubation, the treated cells were analyzed using a FACScan flow cytometer (Becton 
Dickinson, USA). 
2.8 Pharmacokinetics 
The bioavailability of the pure BUF was compared to that of BUF incorporated 
in the C-LC-ME-BUF carriers. Wistar rats were used in these experiments. They were 
divided into two groups (n = 6). Pure BUF or C-LC-ME-BUF formulations were 
given to the rats at a dose of 10 mg/kg. After the parenteral administration, 
approximately 0.5 mL of blood was collected from the ocular vein into a heparinized 
tube at times 5, 15, 30, 45, 60, 90, 120, 240, 360 and 600 minutes. The collected 
blood samples were analyzed by HPLC after corresponding treatment. The 
pharmacokinetic parameters such as clearance (CL) and area under the 
concentration-time curve (AUC) were calculated using the pharmacokinetic software 
3P97 (Mathematics Pharmacological Committee of the Chinese Academy of 
Pharmacology, Shanghai, People’s Republic of China). 
2.9 Statistic analysis  
Data are expressed as mean ± SD and were analyzed with the student’s t-test. The 
difference between two means was considered statistically significant when P < 0.05. 
 
 
Result and discussion 
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1. Structural characterization of the LC-ME and LC-ME-BUF systems 
The multicomponent B-LC-ME and C-LC-ME mixtures were homogeneously 
formed upon physical agitation. The principal difference between the B-LC-ME and 
C-LC-ME compositions was in the incorporated oil amount. The water content was 
systematically varied along the lines B−B4 and C−C4, which are shown in the 
pseudo-ternary phase diagram in Fig. 1b. Structural characterizations were performed 
by SAXS for the oil/surfactant/water compositions depicted in Table S1.  
The SAXS results for the samples of varying water contents are presented in Fig. 
2. They indicate that the B-LC-ME and C-LC-ME systems were both of 
microemulsion organization (points B and C in Fig. 1b) before the onset of their 
dilution by water along the lines B−B4 and C−C4.  
 
 
 
Fig. 2 SAXS patterns of B-LC-ME (panel (a)) and C-LC-ME systems (panel (b)) 
recorded at increasing water content along the corresponding lines of the 
pseudo-ternary phase diagram (Fig. 1b, Table S1). The water contents of the samples 
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are indicated for every plot in the figure.  
 
 
The smooth black curves in Fig. 2a (sample B) and Fig. 2b (sample C) display 
correlation peak maxima in the SAXS patterns. The latter are typical for 
microemulsion-type oil/surfactant/water systems as well as for sponge-type 
lipid/water systems [42,43]. The more hydrated samples B1 to B4 and C1 to C4 
display first and second orders of Bragg diffraction peaks and therefore characterize a 
lamellar structure or a phase of multilamellar onions (spacing ratio of 1:2:3) 
[23,42,43]. The q-vector values for the Bragg diffraction maxima in sample B1 are 
equal to q1 = 0.042 Å-1 and q2 = 0.084 Å-1. The Bragg peak maxima of the lamellar 
liquid crystalline structure determine the interlayer repeat distance, d, through the 
relationship d =2.n/q, where n is the order of the Bragg peak. This equation yielded a 
repeat spacing value d = 14.9 nm for the multilamellar onions generated in sample B1. 
Therefore, the SAXS results evidence a phase transition from a microemulsion phase 
to a lamellar liquid crystalline structure in the investigated multicomponent 
amphiphilic mixtures. Considering that the recorded Bragg peaks are less intense as 
compared to those for a well-ordered lamellar phase at this hydration level, it may be 
suggested that multilamellar onion vesicles are formed under such conditions. In 
addition, one observes a tendency of emergence of an additional peak at lower 
q-vectors with the increase of the water content. This implies a coexistence of the 
multilamellar structures with some microemulsion content (samples B3, B4, C3 and 
C4) upon approaching the phase boundary (Fig. 1b) [44].  
The comparison of the SAXS patterns for samples B1 and C1 is done in Fig. 3a. 
It demonstrates that both samples are of lamellar structures. The repeat distance, d, 
was found to be larger for sample B1, for which the Bragg peaks maxima were 
positioned at lower q-vector values. With the increase of the oil content in the lamellar 
structures (from C1 to B1), the interaction between the aqueous layers is reduced 
because the augmented oil content increases the distance between the aqueous 
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channels. This will decrease the electrostatic or dipole-dipole interactions among the 
aqueous channels, which is inversely proportional to the distance. This effect can be 
due to the thickening of the oil reservoirs created by the hydrophobic moieties of the 
surfactant molecules. The arising structural difference in the packing of the two 
multilamellar structures may provoke differences in their controlled release properties. 
These effects will be investigated below.  
 
 
Fig. 3. Comparison of the SAXS patterns of samples B1 and C1 (a) and of B5 and C5 
(d). Cryo-TEM images of sample B5 (e) and C5 (f). Dynamic viscosity (b) and energy 
storage modulus (c) of samples B1 and C1. 
 
 
The structural features of samples containing high water content ~90% w/w 
(points B5 and C5 belonging to the CE region of the diagram in Fig. 1b) are also 
compared. The scattering curves in Fig. 3d revealed that the correlation peak 
maximum of sample B5 is shifted to a lower q-vector value with regard to that of 
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sample C5. This implies that the distances between the surfactant aggregates in the 
aqueous dispersion should be larger. Additional repulsion is required to keep the 
droplets apart at larger distance. This output was verified by DLS experiments as well 
as by Cryo-TEM imaging of the studied dispersions. The particle size measurements 
by DLS established that sample B5 exhibits a mean particle diameter dH=24.3±0.8 nm. 
Indeed, the diameter was slightly bigger than that determined for sample C5, 
dH=18.6±0.5 nm.  
The performed cryo-TEM analysis confirmed the SAXS and DLS results. Fig. 3 
(e and f) clearly shows that samples B5 and C5 are constituted by microemulsions of 
spherical droplets. The latter are homogeneously dispersed and display small particle 
sizes (below 25 nm). The comparison performed at a same magnification scale 
revealed that the mean droplet sizes in samples B5 and C5 slightly differ as 
determined above.  
The structural characterization of the drug-loaded carriers by SAXS established 
that the BUF encapsulation has a pronounced influence on the scattering curves of the 
B-LC-ME-BUF and C-LC-ME-BUF systems. Representative SAXS patterns for the 
different structural organizations, corresponding to the ME, LC and CE regions of the 
diagram, are shown in Fig. 4. The obtained SAXS plots demonstrate that the internal 
structures of the drug-loaded carriers are preserved after BUF encapsulation. However, 
the positions of the Bragg peaks (or the correlation peaks bumps) are displaced in the 
direction of smaller q-vector values. This indicates that the interlayer spacings of the 
samples increase to different degrees depending on the structural type of the blank 
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carriers (ME, LE or CE). At ME  region, maximum peak of B-LC-ME becomes 
sharper after loading BUF, it points that the interaction between ME increases, which 
may due to excluded volume effect. For C-LC-ME there is an opposite phenomenon 
after  loading BUF, maximum peak becomes blunt and the peak value moved to 
smaller q, which means a larger distance and a lower concentration of droplets. At LC 
region, the repeat distance of B-LC-ME and C-LC-ME are all increase and peaks 
become smaller, less ordering after loading BUF. These data evidenced that the BUF 
molecules are successfully encapsulated, and thus the structural parameters of the host 
carrier systems are modified. Taking into account the considerable modification of the 
SAXS patterns in Fig. 4, a high degree of BUF encapsulation in these samples can be 
suggested. This conclusion is supported also by the direct determination of the 
entrapment efficiency of BUF in these carriers (see the section below). 
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Fig. 4. SAXS patterns of BUF drug-loaded carriers (red plots): B-LC-ME-BUF (left 
column) and C-LC-ME-BUF (right column) versus blank carriers (black plots) 
characteristic of the examined three regions of the pseudo-ternary phase diagram: 
microemulsion region ME (a), liquid crystal LC region (b), and coarse emulsion 
region CE (c). 
 
 
It should be noted that bufalin was dissolved in ethanol for the preparation of 
drug-loaded carriers. The recommended dosage of ethanol injection is 5-10% [45]. 
The maximum content in these samples is 7.8%, which is within the safe range. 
Ethanol, included in the formulations, may not only improve the solubility of the drug 
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BUF, but also contribute to the formation and stabilization of lyotropic liquid 
crystalline phases. Ethanol may penetrate into the surfactant membrane, modify its 
organization, increase its fluidity and reduce the system viscosity [41]. The above data 
show that the structural parameters of the B-LC-ME-BUF and C-LC-ME-BUF liquid 
crystalline structures are more sensitive to the BUF loading as compared to the 
water-diluted CE dispersions.  
 
3.2 Encapsulation efficiency, drug loading, and rheological characterization of 
the carriers in relation to bufalin release 
Table S2 shows the encapsulation efficiency (EE) and drug loading (DL) values 
determined for freshly prepared B-LC-ME-BUF and C-LC-ME-BUF carriers. We 
found that the EE values for BUF entrapment are superior to 90%. No significant 
changes in the drug loading and drug entrapment efficiencies were observed for the 
investigated compositions during 90 days of carrier storage. The high EE and DL of 
BUF in the LC-ME carriers should be related to its lipophilic nature and its affinity 
for the membrane compartment reservoirs of the lyotropic lamellar phase.  
The release profiles of BUF from the B-LC-ME-BUF and C-LC-ME-BUF 
carrier systems are shown in Fig. 5. The release of BUF from the free-drug suspension 
was investigated as a control. Fig. 5 demonstrates that more than 90% of BUF was 
rapidly released from the pure drug suspension within 12 h. The B-LC-ME-BUF and 
C-LC-ME-BUF formulations showed smooth release curves of a similar trend. In this 
case, no burst release was observed from the B-LC-ME-BUF and C-LC-ME-BUF 
carriers. The obtained result is consistent with their high encapsulation efficiency. We 
established that the release rate of BUF from the C-LC-ME-BUF formulation was 
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slower than that from B-LC-ME-BUF. The cumulative release of BUF in the 
C-LC-ME-BUF system was only 48.3±2.8% after 96 h. The corresponding value for 
the B-LC-ME-BUF sample was 67.9±3.1%. The release curve of bufalin follow the 
square root of time kinetics (Fig. S2) showed a linear relationship. Generally it 
suggested the mesophases have a diffusion controlled release rate [48]. The 
established sustained release behavior is in agreement with the results obtained in the 
structural SAXS (Fig. 4) and the rheological (Fig. 3) experiments. 
 
Fig. 5. Cumulative in vitro release of bufalin (BUF) from aqueous suspension 
(squares) and from B-LC-ME-BUF (circles) and C-LC-ME-BUF carriers (triangles) 
at 37°C. 
 
For better understanding of the different controlled release profile of the 
investigated carriers, we considered the arguments of Wu et al. [17] who has pointed 
out the role of the different viscosities of the multicomponent systems. The authors 
have emphasized that the amphiphilic compositions may enable the formation of 
different LC structures such as lamellar (Lα), cubic and hexagonal (HⅡ) mesophases, 
which are characterized by different rheological properties influencing the drug 
release profiles [17].  
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Taking into account that the structures of the B-LC-ME series, shown in Fig. 2, 
are similar to those of the C-LC-ME samples, we proceeded to additional experiments 
focusing on the rheology of the two groups of formulations. Samples B1 and C1 were 
selected for rheological experiments because they involved the same hydration levels, 
in same aqueous medium, and were both prepared from the ME region of the diagram. 
The SAXS results revealed that these two samples have liquid crystalline structures 
(Fig. 3a). 
Fig. 3(b and c) presents the rheological data obtained for samples B1 and C1 of 
the B-LC-ME and C-LC-ME series, respectively. They indicate that the B-LC-ME 
and C-LC-ME carriers, prepared from the microemulsion region, are Newtonian 
fluids. The determined dynamic viscosities are in the range of few mPa-s (Fig. 3b), 
which evidences that these formulations are appropriate for injection use [17].  
At variance, samples B1 and C1, prepared in the lyotropic liquid crystal (LC) 
region, showed non-Newtonian fluid properties. They were characterized by 
significantly higher viscosities as compared to the MEs formulations. Despite the 
similarity of the condensed phase multilamellar structures, the viscosity of sample C1 
was higher than that of sample B1. Both carriers exhibited shear-thinning properties 
(Fig. 3b and 3c). The viscosities decreased exponentially upon increasing the shear 
rate. It is worth noting that sample C1 displayed shear-thinning behavior at low shear 
rates. However, shear thickening phenomenon was observed to a certain extent when 
the shear rate increased. This may be due to changes in the internal structure of the 
liquid crystalline phase upon application of the shear stress, which may result in 
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multilayer vesicle formation [23]. Fig. S1 present the curve of shear stress curve as a 
function of the shear rate B-LC-ME, C-LC-ME C1and B1. 
The established dynamic rheological properties of samples B1 and C1 
demonstrated typical characteristics for a lamellar LC phase [23]. The energy storage 
(elastic) modulus (G') was greater than the loss (viscous) modulus (G") at low shear 
stresses. At higher ones, the energy storage modulus of sample C1 was similar to that 
of B1 (Fig. 3c). However, the strain of sample C1 was obviously higher than that of 
sample B1. It may be suggested that this effect may be relevant to the differences in 
the drug release profiles of the carriers[47].  
 
3.3 Biological evaluation of the carriers in cell experiments and in vivo 
pharmacokinetics  
Fig. 6a presents the cytotoxicity of the investigated formulations 
(B-LC-ME-BUF, C-LC-ME-BUF, blank B-LC-ME and C-LC-ME carriers, and free 
BUF drug), which was evaluated with the A549 cell. The obtained data showed that 
the blank B-LC-ME and C-LC-ME carriers have no obvious toxicity. This implies 
that the cell death, resulting from the B-LC-ME-BUF and C-LC-ME-BUF treatments, 
should be primarily due to the BUF release. Besides, the cytotoxic effect of BUF on 
the A549 cells was enhanced after its incorporation in the LC-ME carriers. The 
improved penetration of BUF into the cells and the enhanced intracellular drug 
accumulation may be explained by the fact that LC-ME may carry the drug into the 
cancer cells through endocytosis. Therefore, the B-LC-ME-BUF and C-LC-ME-BUF 
  20
formulations should have high potential for use in cancer therapy. The IC50 values of 
every experimental group are summarized in Table S3. BUF encapsulated in 
C-LC-ME displayed the lowest IC50 value. This result suggests that the 
C-LC-ME-BUF formulation may significantly improve the bioavailability of BUF.  
 
Fig. 6. (a) In vitro cytotoxicity of BUF, B-LC-ME-BUF and C-LC-ME-BUF 
determined with human lung carcinoma A549 cells (A: control group, B: B-LC-ME, 
C: C-LC-ME, D: BUF, E: C-LC-ME-BUF, F: B-LC-ME-BUF); (b) Plasma 
concentration versus time curves for C-LC-ME-BUF and free BUF; P < 0.05. 
 
Apoptosis represents an important mechanism for the inhibition of cancer cell 
proliferation by anticancer agents. The apoptotic profile of free BUF, B-LC-ME-BUF 
and C-LC-ME-BUF in A549 cells was evaluated by flow cytometry. Table 1 
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demonstrates that the C-LC-ME-BUF induced enhanced apoptosis of the A549 cells 
(53.97%) as compared to the B-LC-ME-BUF formulation (39.44%) and the free drug 
(BUF) suspension (37.15%). The data show that the free BUF induces apoptosis of 
the A549 cells at the same extent as the B-LC-ME carriers. However, the apoptosis 
rate was markedly increased for BUF encapsulated in the C-LC-ME carriers. This 
might be due to the better uptake and the greater accumulation of BUF into A549 
cells in a C-LC-ME encapsulated state. The performed biological tests revealed that 
the C-LC-ME-BUF carriers exerted a greater effect on the A549 cells as compared to 
free BUF and the B-LC-ME-BUF formulation. This finding gives a priority to 
C-LC-ME as a suitable drug delivery system of BUF.  
 
Table 1.  Apoptosis rate of A549 cells determined at drug concentration of 7 ng/ml. 
 Apoptosis rate（%） Survival rate（%） 
Free BUF drug 37.15 60.53 
B-LC-ME-BUF 39.44 58.46 
C-LC-ME-BUF 53.97 45.08 
 
Based on the obtained results from the in vitro cell culture experiments, the 
C-LC-ME-BUF carriers were selected for in vivo pharmacokinetic experiments with 
rats through intragastric administration. We examined the sustained release capacity 
of the C-LC-ME-BUF. The plasma concentration versus time curves for 
C-LC-ME-BUF and free BUF are presented in Fig. 6b, which was in the safe range of 
bufalin [46].  
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The pharmacokinetic parameters examined in this work are summarized in Table 
2. The sustained release system C-LC-ME-BUF was compared with the free drug. 
The values of the parameters AUC 0-τ,  MRT and t1/2 were 1.39, 1.83 and 2.15 times 
higher for C-LC-ME-BUF than those for the free BUF. The fact that Cmax and Tmax of 
C-LC-ME-BUF were higher than those of the control group (BUF) indicated that the 
initial burst release can be significantly reduced by the formulation. The 
C-LC-ME-BUF carrier produced highest blood concentrations evidently due to the 
fact that C-LC-ME-BUF is able to slowly release the drug.  
The high AUC 0-τ, AUC 0-∞ and t1/2 values indicated that C-LC-ME-BUF has a 
higher consumption rate than the free BUF. Therefore, loading of BUF in C-LC-ME 
appears to be efficient in prolonging the retention time of BUF in the blood. Despite 
that the C-LC-ME showed good sustained release in the in vitro release experiment, it 
was not consistent with the in vivo pharmacokinetic experiments. The possible reason 
might be the formation of a liquid crystalline structure, which plays a key role in the 
sustained release and shear-thinning properties. The shear rate from the animal 
movement may lower the viscosity and increase the biodistribution of the bufalin 
drug.  
 
Table 2.  Pharmacokinetic parameters determined for C-LC-ME-BUF carriers with 
regard to the free drug BUF.  
 Cmax 
(μg/mL) 
Tmax 
(min) 
t1/2 
(min) 
MRT 
(h) 
AUC 0-τ 
(μg/mL·h) 
AUC 0-∞ 
(μg/mL·h)
C-LC-ME-BUF 4.10 1 7.87 11.11 22.28 27.60 
BUF 3.71 0.25 3.66 6.05 15.97 27.44 
Notes: τ, the end time of the dosage interval. 
 
Conclusion  
 
In this work, we identified conditions for fabrication of sustained-release 
formulations of the poorly soluble anticancer drug bufalin. The in situ occurring phase 
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transition from microemulsions to lamellar liquid crystalline structures, underlying the 
preparation of the BUF drug-loaded carriers, was characterized by SAXS. Optimal 
drug loading was achieved for the C-LC-ME-BUF system. The latter provided high 
encapsulation efficiency and drug loading, long-term stability, and sustained-release 
properties. The IC50 values, determined in cytotoxicity experiments with human lung 
carcinoma A549 cells, proved 1.4 times enhancement of the cytotoxicity exerted by 
the C-LC-ME-BUF carriers in comparison to that of the pure BUF suspension. In 
addition, the C-LC-ME-BUF carriers considerably increased the number of apoptotic 
cancer cells. This might result from the improved bioavailability of BUF encapsulated 
in C-LC-ME as compared to the BUF drug alone. Pharmacokinetic experiments with 
rats showed that bufalin loaded in C-LC-ME carriers can prolong the retention time of 
the drug in the blood. In perspective, the established sustained-release drug profiles 
present interest for in vivo evaluation of the anticancer effects of the C-LC-ME-BUF 
systems. 
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